RIGL Q4 2019 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M-59.3% YoY

Gross Profit

$15M98.8% margin

Operating Income

-$17M-112.6% margin

Net Income

-$17M-111.7% margin

EPS (Diluted)

$-1.03

QoQ Revenue Growth

-26.2%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$148M

Total Liabilities

$94M

Stockholders' Equity

$54M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$38M	-59.3%
Gross Profit	$15M	$38M	-59.6%
Operating Income	-$17M	$3M	-784.7%
Net Income	-$17M	$3M	-632.8%

Revenue Segments

Gross Product

$16M65%

Product

$14M55%

Contract Revenues From Collaborations

$2M6%

Research And Development Services And Others

-$376,000-1%

Discounts And Allowances

-$3M-10%

License

-$4M-14%